IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma

Kishi, Seiji; Minato, M.; Saijo, Atsuro; Murakami, Naoka; Tamaki, Masanori; Matsuura, Motokazu; Murakami, Taichi; Nagai, Kojiro; Abe, Hideharu; Nishioka, Yasuhiko; Doi, Toshio

doi:10.2169/internalmedicine.9814-17

Cited by 55 publications

(36 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This led to complete [ 64 , 70 ] or partial [ 67 ] remission, the requirement of additional immunosuppressive medications such as mycophenolate mofetil (because treatment with high-dose corticosteroids had an insufficient effect and as a standard of care to treat the glomerulopathies) to obtain remission though followed by relapse [ 68 ], and no recovery in dialysis-dependent end-stage renal disease [ 69 ]. IgA nephropathy developed in two patients receiving nivolumab [ 71 , 72 ] and in one patient treated with nivolumab plus ipilimumab [ 64 ]. Drug discontinuation [ 72 ] plus steroid therapy [ 64 ] was associated with remission, whereas the other case showed a more severe AKI and in addition required renal replacement therapies for 5 months before recovery [ 71 ].…”

Section: Discussionmentioning

confidence: 99%

“…IgA nephropathy developed in two patients receiving nivolumab [ 71 , 72 ] and in one patient treated with nivolumab plus ipilimumab [ 64 ]. Drug discontinuation [ 72 ] plus steroid therapy [ 64 ] was associated with remission, whereas the other case showed a more severe AKI and in addition required renal replacement therapies for 5 months before recovery [ 71 ]. Acute focal segmental necrotizing pauci-immune glomerulonephritis was also noted in two patients—one treated with nivolumab and one with nivolumab combined with ipilimumab [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations

Piscitani

Sirolli

Liberato

et al. 2020

IJMS

View full text Add to dashboard Cite

Cancer patients have an incidence of about 60% kidney disease development and are at elevated risk of acute renal damage. Kidney disease in these patients is frequently associated with nephrotoxicity from the ongoing oncological treatment. New anticancer therapeutic strategies, such as targeted therapies and immunotherapies, offer substantial benefits in the treatment of many neoplasms. However, their use is associated with significant nephrotoxicity, which qualitatively differs from that seen with traditional cytotoxic chemotherapy, while the underlying mechanisms are complex and still to be clearly defined. Nephrologists need to be knowledgeable about the array of such renal toxicities for effective collaboration with the oncologist in the prevention and management of kidney involvement. Renal adverse effects may range from asymptomatic proteinuria to renal failure, and their prompt identification and timely treatment is essential for optimal and safe care of the patient. In this article, after presenting clinical cases we discuss the differing renal toxicity of three novel anticancer agents (aflibercept, dasatinib, and nivolumab) and possible measures to counter it.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations

Piscitani

Sirolli

Liberato

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Notably, a few reports identified IgA nephropathy as an irAE. Kishi et al reported a case of nivolumab-associated IgA nephropathy (3). The patient was a 72-year-old man who was treated with nivolumab for lung squamous cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma

et al. 2020

View full text Add to dashboard Cite

Immune checkpoint inhibitors (CPIs), including pembrolizumab, are becoming common oncological treatments. CPIs have been associated with a significant risk of developing immune-related adverse events (irAEs), such as nephritis and interstitial nephritis. However, the occurrence of glomerulonephritis has only rarely been reported. We herein present the case of a 75-year-old woman with non-small cell lung carcinoma (NSCLC) who developed proteinuria and microscopic hematuria during treatment with pembrolizumab. Renal biopsy revealed tubulointerstitial nephritis and IgA nephropathy. Considering that a urinalysis showed no abnormality before treatment, the condition might have been induced by pembrolizumab. In this report, we focus on the correct diagnosis and management of renal irAEs, which remain controversial.

show abstract

“…Additionally, compared with the standard diet, this formula food provides energy, high-quality protein and balanced nutrition, which would be expected to improve the nutritional status, as was suggested by the higher serum albumin level. Although there have been major advances in the treatment of various cancers, postoperative recurrence and metastasis remain a problem [21][22][23]. There is evidence that even after surgery, dormant tumor cells can remain in the body for a long time [24].…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of a Formula Food for Preventing Postoperative Recurrence in a Tumor Dormancy Model

Zhang¹,

Chen²,

Miao³

et al. 2019

Journal of Nutritional Oncology

View full text Add to dashboard Cite

Objective To establish a lung cancer dormancy mouse model and verify the effects of Wushen (WS), a formula food, on postoperative recurrence. Methods We established a Lewis cell tumor dormancy model system that definitively links surgery and the subsequent wound-healing response to the outgrowth of lung cancer cells. We used this model to observe the effects of WS on the postoperative recurrence and the nutritional status of the mice. Finally, the immunocyte subtypes and cytokine levels in the serum and spleens of mice were detected by flow cytometry and ELISA. Results The recurrence rate in the WS group was obviously lower than that in the control group. Wushen increased the body weights and serum albumin levels of the mice. The levels of NK, Gr1 + CD11b + CD3 + CD8 + and CD3 + CD4 + T cells in the spleens of mice in the WS group were also increased. Compared with the control group, the levels of CD4 + IFN-γ + , CD4 + IL-2 and CD4 + /IL-10 + in the spleens of mice in the WS group were decreased. Wushen also seemed to decrease the levels of IL-6 and TNF-α, but the decrease was not significant. Conclusion The postoperative lung cancer recurrence model was successfully established. Wushen inhibited postoperative recurrence, apparently by regulating the level of immune cell subtypes and cytokines in the serum and spleen.

show abstract

IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma

Cited by 55 publications

References 19 publications

Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations

Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations

Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma

The Efficacy of a Formula Food for Preventing Postoperative Recurrence in a Tumor Dormancy Model

Contact Info

Product

Resources

About